Drug shortage
Etomidate Injection · Mylan Institutional, a Viatris Company
FDA drug shortage · Current · updated Apr 17, 2025
Key facts
| Generic name | Etomidate Injection |
|---|---|
| Proprietary name | Etomidate |
| Company | Mylan Institutional, a Viatris Company |
| Presentation | Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10) |
| Dosage form | Injection |
| Strength | 2 mg/1 mL |
| Status | Current |
| Therapeutic category | Anesthesia |
| Package NDCs | 67457-902-10 |
| First posted | Oct 5, 2022 |
| Last updated | Apr 17, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: